| Code | CSB-RA004844MB2HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is a research-grade biosimilar to Leronlimab, designed to specifically target CCR5 (C-C chemokine receptor type 5), a G protein-coupled receptor expressed primarily on T cells, macrophages, and dendritic cells. CCR5 functions as a co-receptor for HIV-1 entry into host cells and plays a critical role in immune cell trafficking and inflammatory responses. The receptor is implicated in various pathological conditions including HIV/AIDS infection, where it facilitates viral entry, as well as cancer metastasis, graft-versus-host disease, and inflammatory disorders where CCR5-mediated chemotaxis contributes to disease progression.
Leronlimab is a humanized IgG4 monoclonal antibody that binds to CCR5 and blocks the interaction between the receptor and its ligands, including CCL3, CCL4, and CCL5, as well as preventing HIV envelope protein binding. This biosimilar antibody serves as a valuable research tool for investigating CCR5-mediated signaling pathways, studying HIV pathogenesis mechanisms, exploring immune cell migration in inflammatory contexts, and evaluating potential therapeutic strategies targeting CCR5 in oncology and immunology research.
There are currently no reviews for this product.